Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults

References

• Hymes KB, Cheung T, Greene JB, et al. Kaposi’s sarcoma in homosexual men-a report of eight cases. Lancet. 1981;2:598–600.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control (CDC). Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men - New York City and California. MMWR Morb Mortal Wkly Rep. 1981;30(25):305–308.
   PubMedGoogle Scholar
• Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 8:e81355.
   PubMed Web of Science ®Google Scholar
• Vella S, Schwartländer B, Sow SP, et al. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS. 2012;10:1231–1241.
   Google Scholar
• Balderson BH, Grothaus L, Harrison RG, et al. Chronic illness burden and quality of life in an aging HIV population. AIDS Care. 2013;25:451–458.
   PubMed Web of Science ®Google Scholar
• Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009;17:118–123.
   PubMedGoogle Scholar
• Pathai S, Bajillan H, Landay AL, et al. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci. 2014;69:833–842.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–1126.
   PubMed Web of Science ®Google Scholar
• Wing EJ. HIV and aging. Int J Infect Dis. 2016;53:61–68.
   PubMed Web of Science ®Google Scholar
• Gazzola L, Tincati L, d’Arminio Monforte A. Noninfectious HIV-related comorbidities and HAART toxicities: choosing alternative antiretroviral strategies. HIV Ther. 2010;4:553–565.
   Google Scholar
• Margolis AM, Heverling H, Pham PA, et al. A review of the toxicity of HIV medications. J Med Toxicol. 2014;10:26–39.
   PubMedGoogle Scholar
• DAD Study Group; Friis-Møller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356(17):1723–1735.
   PubMed Web of Science ®Google Scholar
• Bedimo R, Maalouf NM, Zhang S, et al. Risk of osteoporotic fractures associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825–831.
   PubMed Web of Science ®Google Scholar
• Hall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773–780.
   PubMed Web of Science ®Google Scholar
• Kheloufi F, Allemand J, Mokhtari S, et al. Psychiatric disorders after starting DTG: report of four cases. Aids. 2015;29:1723–1725.
   PubMed Web of Science ®Google Scholar
• De Boer M, Van den Berk G, Van Holten N, et al. Intolerance of DTG containing cART regimens in real life clinical practice. Aids. 2016;30:2831–2834.
   PubMed Web of Science ®Google Scholar
• Dorjee K, Baxi SM, Reingold AL, et al. Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study. BMC Infect Dis. 2017;17:708.
   PubMed Web of Science ®Google Scholar
• Sculier D, Gayet-Ageron A, Battegay M, et al. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. BMC Infect Dis. 2017;17:476.
   PubMed Web of Science ®Google Scholar
• Baril JG, Angel JB, Gill MJ, et al. Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-naive or ARV-experienced, virologically suppressed patients. PLoS One. 2016;11:e0148231.
   PubMed Web of Science ®Google Scholar
• Achhra AC, Mwasakifwa G, Amin J, et al. Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis. Lancet HIV. 2016;3:e351–360.
   PubMed Web of Science ®Google Scholar
• Orkin C, Llibre JM, Gallien S, et al. Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence. HIV Med. 2018;19:18–32.
   PubMed Web of Science ®Google Scholar
• Edelman EJ, Gordon KS, Glover J, et al. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging. 2013;30:613–628.
   PubMed Web of Science ®Google Scholar
• Badri M, Maartens G, Mandalia S, et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Medicine. 2006;3:e4.
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society Guidelines. 2017. Version 8.2. [cited 2018 Jun 26th]. Available from: http://www.eacsociety.org/files/guidelines_9.0-english.pdf.
   Google Scholar
• Società Italiana di Malattie Infettive e Tropicali (SIMIT). Linee guida italiane sull’utilizzo dei farmaci anti-retrovirali e sulla gestione diagnostico-clinica delle persone coinfezione da HIV. Available at: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2696_allegato.pdf. Last accessed 2018 Jun 26th.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. [cited 2018 Jun 26th]. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• Hare S, Smith SJ, Métifiot M, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011;80:565–572.
   PubMed Web of Science ®Google Scholar
• Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013;52:981–994.
   PubMed Web of Science ®Google Scholar
• Sanford M. Rilpivirine. Drugs. 2012;72:525–541.
   PubMed Web of Science ®Google Scholar
• Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next generation non nucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemoter. 2010;54:718–727.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391:839–849.
   PubMed Web of Science ®Google Scholar
• Capetti AF, Sterrantino G, Cossu MV, et al. Switch to dolutegravir plus rilpivirine dual therapy in cART-experienced subjects: an observational cohort. PLoS One. 2016;11:e0164753.
   PubMed Web of Science ®Google Scholar
• Capetti AF, Cossu MV, Sterrantino G, et al. Dolutegravir plus rilpivirine as a switch option in cART-experienced patients: 96-Week Data. Ann Pharmacother. 2018;52:740–746.
   PubMed Web of Science ®Google Scholar
• Gantner P, Cuzin L, Allavena C, et al. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study. HIV Med. 2017;18:704–708.
   PubMed Web of Science ®Google Scholar
• Palacios R, Mayorga M, González-Domenech CM, et al. Safety and efficacy of dolutegravir plus rilpivirine in treatment-experienced HIV-Infected Patients: the DORIVIR study. J Int Assoc Provid AIDS Care. 2018;17:2325958218760847.
   Google Scholar
• Revuelta-Herrero JL, Chamorro-de-Vega E, Rodríguez-González CG, et al. Effectiveness, safety, and costs of a treatment switch to dolutegravir plus rilpivirine dual therapy in treatment-experienced HIV patients. Ann Pharmacother. 2018;52:11–18.
   PubMed Web of Science ®Google Scholar
• Díaz A, Casado JL, Dronda F, et al. Dolutegravir plus rilpivirine in suppressed heavily pre-treated HIV-infected patients. Abs TUPDB0106 International AIDS Conference, 2016 July 18–22; Durban, South Africa.
   Google Scholar
• Gubavu C, Prazuck T, Niang M, et al. Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients. J Antimicrob Chemother. 2016;71:1046–1050.
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807–1818.
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, noninferiority SAILING study. Lancet. 2013;382:700–708.
   PubMed Web of Science ®Google Scholar
• Raffi F, Rachlis A, Brinson C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS. 2015;29:167–174.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to Dolutegravir discontinuation in women and older patients. HIV Med. 2017;18:56–63.
   PubMed Web of Science ®Google Scholar
• Elzi L, Erb S, Furrer H, et al. Adverse events of raltegravir and dolutegravir. Aids. 2017;31:1853–1858.
   PubMed Web of Science ®Google Scholar
• Keeshin SW, Feinberg J. Evaluation of dolutegravir safety for the treatment of HIV-1. Expert Opin Drug Saf. 2015;14:141–147.
   PubMed Web of Science ®Google Scholar
• Hill AM, Mitchell N, Hughes S, et al. Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials. Curr Opin HIV AIDS. 2018;13:102–111.
   PubMed Web of Science ®Google Scholar
• Zash R, Jacobson DL, Diseko M, et al. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. Lancet Glob Health. 2018;6:e804–e810.
   PubMed Web of Science ®Google Scholar
• Bornhede R, Soeria-Atmadja S, Westling K, et al. Dolutegravir in pregnancy-effects on HIV-positive women and their infants. Eur J Clin Microbiol Infect Dis. 2018;37:495–500.
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication. FDA to evaluate potential risk of neural tube birth defects with HIV medicine Dolutegravir (Juluca, Tivicay, Triumeq). 2018 May 18.
   Google Scholar
• Haggblom A, Lindback S, Gisslen M, et al. HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014. PLoS One. 2017;12:e0171227.
   PubMed Web of Science ®Google Scholar
• Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238–246.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378:229–237.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. Aids. 2013;27:939–950.
   PubMed Web of Science ®Google Scholar
• Song I, Borland J, Min S, et al. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother. 2011;55:3517–3521.
   PubMed Web of Science ®Google Scholar
• Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteeers. J Antimicrob Chemother. 2011;66:1567–1572.
   PubMed Web of Science ®Google Scholar
• Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62:21–27.
   PubMed Web of Science ®Google Scholar
• Sharma M, Saravolatz LD. Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor. J Antimicrob Chemother. 2013;68:250–256.
   PubMed Web of Science ®Google Scholar
• Aouri M, Barcelo C, Guidi M, et al. Population pharmacokinetics and pharmacogenetics. Analysis of rilpivirine in HIV-1-infected individuals. Antimicrob Agents Chemother. 2016;61:e00899–16.
   PubMed Web of Science ®Google Scholar
• Hussaini T. Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review. Hepat Med. 2016;8:61–68.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. Aids. 2010;24:1667–1678.
   PubMed Web of Science ®Google Scholar
• Weller S, Borland J, Chen S, et al. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. Eur J Clin Pharmacol. 2014;70:29–35.
   PubMed Web of Science ®Google Scholar
• Yombi JC, Pozniak A, Boffito M, et al. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS. 2014;28:621–632.
   PubMed Web of Science ®Google Scholar
• Biver E, Calmy A, Rizzoli R. Bone health in HIV and hepatitis B or C infections. Ther Adv Musculoskelet Dis. 2017;9:22–34.
   PubMed Web of Science ®Google Scholar
• Hoy J, Young B. Do people with HIV infection have a higher risk of fracture compared with those without HIV infection? Curr Opin HIV AIDS. 2016;11:301–305.
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Weitzmann MN. HIV and bone metabolism. Discov Med. 2011;11:385–393.
   PubMed Web of Science ®Google Scholar
• Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482–487.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Lupo S, Parks D, et al. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. AIDS. 2018;32:477–485.
   PubMed Web of Science ®Google Scholar
• Feeney ER, Mallon PW. HIV and HAART-associated dyslipidemia. Open Cardiovasc Med J. 2011;5:49–63.
   PubMedGoogle Scholar
• Quercia R, Roberts J, Martin-Carpenter L, et al. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs.efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig. 2015;35:211–219.
   PubMed Web of Science ®Google Scholar
• Gatell JM, Assoumou L, Moyle G, et al. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS. 2017;31:2503–2514.
   PubMed Web of Science ®Google Scholar
• Afonso P, Auclair M, Caron-Debarle M, et al. Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence. Antivir Ther. 2017;22:645–657.
   PubMed Web of Science ®Google Scholar
• Tebas P, Sension M, Arribas J, et al. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or efavirenz for 96 weeks in the ECHO and THRIVE trials. Clin Infect Dis. 2014;59:425–434.
   PubMed Web of Science ®Google Scholar
• Thamrongwonglert P, Chetchotisakd P, Anunnatsiri S, et al. Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia. HIV Clin Trials. 2016;17:12–16.
   PubMed Web of Science ®Google Scholar
• Mussini C, Lorenzini P, Cozzi-Lepri A, et al. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Medicine. 2018;16:79.
   PubMed Web of Science ®Google Scholar
• Quiros-Roldan E, Magro P, Raffetti E, et al. Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015. BMC Infect Dis. 2018;18:285.
   PubMed Web of Science ®Google Scholar
• Capetti AF, Orofino G, Paladini L, et al. Does simplification to dolutegravir-based dual regimens impact on the CD4+/CD8+ T-cell ratio? AIDS. 2018;32:1083–1084.
   PubMed Web of Science ®Google Scholar
• Belmonti S, Lombardi F, Quiros-Roldan E, et al. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. J Antimicrob Chemother. 2018. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Nwogu JN, Ma Q, Babalola CP, et al. Pharmacokinetic, pharmacogenetic, and other factors influencing CNS penetration of antiretrovirals. AIDS Res Treat. 2016;2016:2587094.
   PubMed Web of Science ®Google Scholar
• Letendre SL, Mills AM, Tashima KT, et al. A study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1–infected, antiretroviral therapy–naive subjects. Clin Infect Dis. 2014;59:1032–1037.
   PubMed Web of Science ®Google Scholar
• Mora-Peris B, Winston A, Garvey L, et al. HIV-1 CNS in vitro infectivity models based on clinical CSF samples. J Antimicrob Chemother. 2016;1:235–243.
   Google Scholar
• Imaz A, Martinez-Picado J, Niubó J, et al. HIV-1-RNA decay and dolutegravir concentrations in semen of patients starting a first antiretroviral regimen. J Infect Dis. 2016;214:1512–1519.
   PubMed Web of Science ®Google Scholar
• Couturier J, Winchester LC, Suliburk JW, et al. Adipocytes impair efficacy of antiretroviral therapy. Antiviral Res. 2018;154:140–148.
   PubMed Web of Science ®Google Scholar
• Gantner P, Lee GQ, Rey D, et al. Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs. J Antimicrob Chemother. 2018;73:1045–1053.
   PubMed Web of Science ®Google Scholar
• Sharkey M, Triques K, Kuritzkes DR, et al. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol. 2005;79:5203–5210.
   PubMed Web of Science ®Google Scholar
• Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010;16:460–465.
   PubMed Web of Science ®Google Scholar
• Hatano H, Strain MC, Scherzer R, et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis. 2013;208:1436–1442.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Buzon MJ, Massanella M, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antiviral Ther. 2012;17:355–364.
   PubMed Web of Science ®Google Scholar
• Rasmussen TA, McMahon JH, Chang JJ, et al. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. Lancet HIV. 2018;5:e221–e230.
   PubMed Web of Science ®Google Scholar
• Girouard MP, Sax PE, Parker RA, et al. The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV Infection in the united states. Clin Infect Dis. 2016;62:784–791.
   PubMed Web of Science ®Google Scholar
• Gupta A, Juneja S, Vitoria M, et al. Projected uptake of new antiretroviral (ARV) medicines in adults in low- and middle-income countries: a forecast analysis 2015-2025. PLoS One. 2016;11:e0164619.
   PubMed Web of Science ®Google Scholar